Analyst Scoreboard: 5 Ratings For Insulet
Portfolio Pulse from Benzinga Insights
Insulet (NASDAQ:PODD) has received mixed analyst ratings over the last three months, with a shift towards more bullish perspectives in the last 30 days. The average 12-month price target for Insulet has been raised to $227.0, indicating a 17.25% increase from the previous target. Analysts from firms like Piper Sandler, JP Morgan, Stifel, Baird, and Morgan Stanley have adjusted their ratings and price targets, reflecting their evolving views on Insulet's market performance. Insulet's financial indicators such as revenue growth, net margin, ROE, ROA, and debt management are highlighted, showcasing the company's strong financial health and performance.
February 23, 2024 | 7:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Insulet has seen a positive shift in analyst ratings, with an increased average 12-month price target of $227.0, reflecting a 17.25% rise. Financial indicators show strong performance, with significant revenue growth and net margin.
The positive shift in analyst ratings and the increase in the average 12-month price target suggest a bullish outlook for Insulet. The company's strong financial indicators, such as revenue growth and net margin, support this positive sentiment. The adjustments in ratings and price targets by analysts from reputable firms further reinforce the potential for stock price appreciation in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100